Covid-19: 5% of Covaxin royalty to ICMR raises questions

This has prompted public health and intellectual property experts to voice concerns. They have questioned the demand for the payout, to be done on a half-yearly basis, and also the basis of its calculation. The payout reflects in the cost of the vaccine, and hence impacts affordability, they told.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3xt4Jy9
via IFTTT